CAR T-Cell Therapy

Binod Dhakal, MD, explores clinicians' safety concerns with using CAR-T therapy in R/R MM, including notable adverse events from recent clinical data and strategies for managing these events in practice.

Binod Dhakal, MD, discusses the latest results from the KarMMA-3 study, which investigated idecabtagene vicleucel (ide-cel) for patients with R/R MM, covering study design, patient population, and key takeaways.

Binod Dhakal, MD, reviews the latest results from the CARTITUDE-4 study, which evaluated ciltacabtagene autoleucel (cilta-cel) versus standard of care in patients with R/R MM, including study design, patient population, and key efficacy findings.

Binod Dhakal, MD, explores the role of CAR-T cell therapy in R/R MM, including an overview of the process, patient selection criteria, and identifying suitable candidates.

Binod Dhakal, MD, discusses the current standard of care for R/R MM, highlighting how treatment decision-making changes for patients who are refractory to lenalidomide and/or bortezomib.

Binod Dhakal, MD, provides a high-level overview of relapsed/refractory multiple myeloma (R/R MM), including the clinical hallmarks, risk factors, and patient stratification.

The result of the FDA's Oncologic Drug Advisory Committee vote on idecabtagene vicleucel for the proposed indication is favorable.

During an Oncologic Drugs Advisory Committee Meeting, the FDA found that ciltacabtagene autoleucel has a favorable benefit/risk profile in relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy and are refractory to lenalidomide.

Introducing a checkpoint inhibitor like nivolumab for patients where chimeric antigen receptor T-cell therapy failed in multiple myeloma is a potential area of interest for researchers.

Six CAR T-cell therapies have gained FDA approval across hematologic malignancy settings. These approvals have spurred further exploration for their use in solid tumors.

The novel cell therapy A2B530 is the first logic-gated cell therapy aimed at selectively killing tumor cells and protecting healthy cells in colorectal cancer.

The latest developments across the fields of stem cell transplantation and cellular therapy were presented at the 2024 Tandem Meetings in San Antonio, Texas, from February 21-24, 2024.

Abdullah M. Khan, MBBS, discusses the recent updates to data on the use of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

A retrospective study of real-world patients showed that immune engager therapies had the best response and progression-free survival rates in patients with multiple myeloma who had a relapse after idecabtagene vicleucel treatment.

A retrospective study demonstrated the feasibility and efficacy of brexucabtagene autoleucel in treating central nervous system involvement in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.

The phase 1 study of HEMO-CAR-T in patients with acute myeloid leukemia can proceed following the lifted clinical hold.

The FDA’s Oncologic Drug Advisory Committee will be held on March 15, 2024, to review data pertaining to the supplemental biologics license application of ide-cel in relapsed or refractory multiple myeloma.

The axicabtagene ciloleucel manufacturing process has received FDA approval for a change to reduce the median turnaround time.

Matthew J. Frigault, MD, MS, discussed follow-up data on the efficacy and safety of CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma, particularly in later-line settings.

Findings from a phase 2 study found that treatment with axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma led to a complete metabolic response of 71%.

In an interview with Targeted Oncology, Daniel Baker, PhD candidate at the University of Pennsylvania, discussed the growing role for CAR T-cell therapies outside of the oncology field.

Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.

Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.

Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.